Last week’s news that J&J is abandoning their coronary stent business was sad, but provided several lessons about poor product development execution and the need for constant innovation. J&J created ...

Johnson & Johnson's (JNJ) announcement that it is getting out of the drug-eluting stent business-- those are the tiny drug-covered tubes inserted into arteries to prevent strokes -- was blamed by many ...

Direct-to-consumer drug advertising is coming under fire from another camp. Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial ...

Johnson & Johnson will stop selling drug-coated heart stents, a former profit driver for the diversified healthcare company that has stumbled due to safety concerns and fierce competition from rival ...

Johnson & Johnson said late Thursday it plans to buy Conor Medsystems for $1.4 billion in cash, a bid by the pharmaceuticals giant to expand its presence in the $6 billion-a-year market for ...

Apparently, Johnson & Johnson didn't want to wait and see what the FDA's expert advisors think of Abbott Laboratories' Xience stent. The company filed suit against Abbott for patent infringement ...

As the long-running battle for dominance in the highly-lucrative stent market continues its twists and turns, Johnson & Johnson will be cheered on news that its Cypher stent has come out on top in a ...

The therapy of deep infiltrating endometriosis places the highest demands. Double-J (DJ) stent insertion is recommended preoperatively. However, we could not find any publication in PubMed that showed ...

NEW YORK (Reuters) - Johnson & Johnson will stop selling drug-coated heart stents, a former profit driver for the diversified healthcare company that has stumbled due to safety concerns and fierce ...

Johnson & Johnson moved to consolidate its position in the market for drug-eluting stents with a $1.4 billion offer for Conor Medsystems. Johnson & Johnson moved to consolidate its position in the ...